Abbott Laboratories stock: TD Cowen keeps USD 135.00 target for Abbott Laboratories stock

Published on 10/19/2026 at 16:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott's quarter brought USD 12.59 billion revenue, up 13.00 percent. Abbott Laboratories stock costs EUR 92.59 on October 19, 2026.

Analyst target and quarterly metrics

On October 16, TD Cowen reaffirmed a USD 135.00 target for Abbott Laboratories stock.
Abbott's latest quarter brought USD 12.59 billion in revenue, up 13.00 percent.
Abbott Laboratories stock costs EUR 92.59 at Lang & Schwarz on October 19, 2026 at 4:42 p.m. CEST.
Abbott's price-to-earnings ratio was 33.34 on October 19, 2026.

Pharma-Campus Architektur-Render Abbott Laboratories US0028241000 Illinois — Abbott Laboratories US0028241000 Architektur-Render moderner Pharma-Campus mit Glas-Stahl-Gebäuden Grünanlagen und Teich Illinois, Illustration mit AI erstellt.

On October 16, 2026, TD Cowen reaffirmed a Buy rating and a USD 135.00 price target for Abbott Laboratories stock, according to TradingView. Against Abbott's USD 103.70 home-market price at 10:53 a.m. ET on October 19, 2026, that target is 30.18 percent higher. Abbott Laboratories stock was trading at EUR 92.59 at Lang & Schwarz on October 19, 2026 at 4:42 p.m. CEST.

Quarterly revenue reached USD 12.59 billion

Abbott's latest quarter, reported on July 16, 2026, delivered USD 12.59 billion in revenue, up 13.00 percent from the year-earlier quarter. Adjusted earnings per share came to USD 1.31, compared with USD 1.28 expected, according to MarketBeat. The figures give the upcoming report a clear benchmark: revenue growth must remain visible while earnings catch up with expectations.

Stock sits below its yearly high

Abbott's USD 103.70 home-market price stood 21.46 percent below its USD 132.03 52-week high and 26.51 percent above its USD 81.97 low on October 19, 2026. The range puts the current quote closer to the middle of the year's spread than to either extreme.

Valuation and October 21 results

Abbott had a market capitalization of USD 179.4 billion and a price-to-earnings ratio of 33.34 on October 19, 2026. The next scheduled report is October 21, 2026, before the US market opens, followed by an earnings call at 9:00 a.m. ET, according to Abbott.

Comparison with peers

Abbott Laboratories: P/E 33.34, market capitalization USD 179.4 billion.

Medtronic (NYSE, USD): minus 1.94 percent, P/E 22.90, market capitalization USD 118.8 billion.

Boston Scientific (NYSE, USD): minus 0.25 percent, P/E 18.01, market capitalization USD 64.2 billion.

The euro quote at Lang & Schwarz

Abbott Laboratories stock was trading at EUR 92.59 at Lang & Schwarz on October 19, 2026 at 4:42 p.m. CEST. The euro quote frames the German-market view while the NYSE valuation and the October 21 reporting date set the next reference points. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.